nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—SLC22A4—larynx—muscle cancer	0.0424	0.0601	CbGeAlD
Amiloride—AOC1—embryo—muscle cancer	0.0294	0.0417	CbGeAlD
Amiloride—SLC9A1—embryo—muscle cancer	0.0282	0.0399	CbGeAlD
Amiloride—ASIC2—tendon—muscle cancer	0.0275	0.039	CbGeAlD
Amiloride—ASIC2—head—muscle cancer	0.0236	0.0334	CbGeAlD
Amiloride—SCNN1G—renal system—muscle cancer	0.0227	0.0322	CbGeAlD
Amiloride—AOC1—renal system—muscle cancer	0.0223	0.0316	CbGeAlD
Amiloride—SLC9A1—smooth muscle tissue—muscle cancer	0.0222	0.0314	CbGeAlD
Amiloride—SLC9A1—renal system—muscle cancer	0.0213	0.0302	CbGeAlD
Amiloride—PLAU—smooth muscle tissue—muscle cancer	0.021	0.0298	CbGeAlD
Amiloride—PLAU—renal system—muscle cancer	0.0202	0.0287	CbGeAlD
Amiloride—SCNN1B—renal system—muscle cancer	0.0192	0.0272	CbGeAlD
Amiloride—SLC9A1—cardiac atrium—muscle cancer	0.0191	0.0271	CbGeAlD
Amiloride—PLAU—cardiac atrium—muscle cancer	0.0181	0.0257	CbGeAlD
Amiloride—SCNN1A—renal system—muscle cancer	0.0177	0.0251	CbGeAlD
Amiloride—AOC1—bone marrow—muscle cancer	0.0168	0.0239	CbGeAlD
Amiloride—SCNN1G—vagina—muscle cancer	0.0164	0.0233	CbGeAlD
Amiloride—AOC1—vagina—muscle cancer	0.0161	0.0229	CbGeAlD
Amiloride—SLC9A1—bone marrow—muscle cancer	0.0161	0.0229	CbGeAlD
Amiloride—PLAU—tendon—muscle cancer	0.0158	0.0224	CbGeAlD
Amiloride—PLAU—bone marrow—muscle cancer	0.0153	0.0217	CbGeAlD
Amiloride—SCNN1D—head—muscle cancer	0.0152	0.0215	CbGeAlD
Amiloride—ASIC1—head—muscle cancer	0.0149	0.0211	CbGeAlD
Amiloride—SCNN1D—testis—muscle cancer	0.0147	0.0208	CbGeAlD
Amiloride—PLAU—vagina—muscle cancer	0.0146	0.0208	CbGeAlD
Amiloride—AOC1—testis—muscle cancer	0.0144	0.0204	CbGeAlD
Amiloride—ASIC1—testis—muscle cancer	0.0144	0.0204	CbGeAlD
Amiloride—SLC9A1—head—muscle cancer	0.0143	0.0202	CbGeAlD
Amiloride—SCNN1B—vagina—muscle cancer	0.0139	0.0197	CbGeAlD
Amiloride—SLC9A1—testis—muscle cancer	0.0138	0.0195	CbGeAlD
Amiloride—PLAU—head—muscle cancer	0.0135	0.0192	CbGeAlD
Amiloride—PLAU—testis—muscle cancer	0.0131	0.0185	CbGeAlD
Amiloride—SCNN1B—head—muscle cancer	0.0128	0.0182	CbGeAlD
Amiloride—SCNN1B—testis—muscle cancer	0.0124	0.0176	CbGeAlD
Amiloride—SCNN1A—head—muscle cancer	0.0119	0.0168	CbGeAlD
Amiloride—SCNN1A—testis—muscle cancer	0.0114	0.0162	CbGeAlD
Amiloride—SLC22A2—renal system—muscle cancer	0.00956	0.0136	CbGeAlD
Amiloride—SLC22A4—renal system—muscle cancer	0.00709	0.0101	CbGeAlD
Amiloride—SLC22A1—renal system—muscle cancer	0.00676	0.00958	CbGeAlD
Amiloride—SLC22A4—tendon—muscle cancer	0.00554	0.00785	CbGeAlD
Amiloride—Hyperuricaemia—Vincristine—muscle cancer	0.0054	0.0193	CcSEcCtD
Amiloride—SLC22A4—bone marrow—muscle cancer	0.00536	0.0076	CbGeAlD
Amiloride—Aplastic anaemia—Dactinomycin—muscle cancer	0.00526	0.0188	CcSEcCtD
Amiloride—SLC22A4—vagina—muscle cancer	0.00514	0.00728	CbGeAlD
Amiloride—Blood uric acid increased—Vincristine—muscle cancer	0.0051	0.0182	CcSEcCtD
Amiloride—SLC22A1—vagina—muscle cancer	0.00489	0.00694	CbGeAlD
Amiloride—Coma—Vincristine—muscle cancer	0.00458	0.0164	CcSEcCtD
Amiloride—Urine output increased—Vincristine—muscle cancer	0.00453	0.0162	CcSEcCtD
Amiloride—SLC22A1—head—muscle cancer	0.00452	0.00641	CbGeAlD
Amiloride—Hyperuricaemia—Etoposide—muscle cancer	0.00437	0.0156	CcSEcCtD
Amiloride—Polyuria—Vincristine—muscle cancer	0.00414	0.0148	CcSEcCtD
Amiloride—Blood uric acid increased—Etoposide—muscle cancer	0.00413	0.0148	CcSEcCtD
Amiloride—Encephalopathy—Methotrexate—muscle cancer	0.00378	0.0135	CcSEcCtD
Amiloride—Hyponatraemia—Vincristine—muscle cancer	0.00365	0.013	CcSEcCtD
Amiloride—Pain in extremity—Vincristine—muscle cancer	0.00363	0.013	CcSEcCtD
Amiloride—Liver disorder—Methotrexate—muscle cancer	0.00356	0.0127	CcSEcCtD
Amiloride—Neutropenia—Dactinomycin—muscle cancer	0.00329	0.0118	CcSEcCtD
Amiloride—Muscular weakness—Vincristine—muscle cancer	0.00321	0.0115	CcSEcCtD
Amiloride—Dysuria—Vincristine—muscle cancer	0.00294	0.0105	CcSEcCtD
Amiloride—Neutropenia—Vincristine—muscle cancer	0.00294	0.0105	CcSEcCtD
Amiloride—Erectile dysfunction—Vincristine—muscle cancer	0.00289	0.0103	CcSEcCtD
Amiloride—Depression—Vincristine—muscle cancer	0.00279	0.00998	CcSEcCtD
Amiloride—Cramp muscle—Etoposide—muscle cancer	0.00265	0.00948	CcSEcCtD
Amiloride—Hyperuricaemia—Methotrexate—muscle cancer	0.00262	0.00936	CcSEcCtD
Amiloride—Alopecia—Dactinomycin—muscle cancer	0.00249	0.00889	CcSEcCtD
Amiloride—Blood uric acid increased—Methotrexate—muscle cancer	0.00247	0.00884	CcSEcCtD
Amiloride—Neutropenia—Etoposide—muscle cancer	0.00238	0.00851	CcSEcCtD
Amiloride—Aplastic anaemia—Methotrexate—muscle cancer	0.00228	0.00815	CcSEcCtD
Amiloride—Hyperuricaemia—Doxorubicin—muscle cancer	0.00227	0.00811	CcSEcCtD
Amiloride—Alopecia—Vincristine—muscle cancer	0.00222	0.00794	CcSEcCtD
Amiloride—Coma—Methotrexate—muscle cancer	0.00222	0.00794	CcSEcCtD
Amiloride—Jaundice—Etoposide—muscle cancer	0.00221	0.00791	CcSEcCtD
Amiloride—Urine output increased—Methotrexate—muscle cancer	0.0022	0.00785	CcSEcCtD
Amiloride—Gynaecomastia—Methotrexate—muscle cancer	0.00217	0.00777	CcSEcCtD
Amiloride—Blood uric acid increased—Doxorubicin—muscle cancer	0.00214	0.00766	CcSEcCtD
Amiloride—Neck pain—Doxorubicin—muscle cancer	0.00213	0.00761	CcSEcCtD
Amiloride—Back pain—Vincristine—muscle cancer	0.00212	0.00757	CcSEcCtD
Amiloride—Hepatocellular injury—Doxorubicin—muscle cancer	0.0021	0.00752	CcSEcCtD
Amiloride—Hyperkalaemia—Doxorubicin—muscle cancer	0.00207	0.00739	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—TFE3—muscle cancer	0.00201	0.136	CbGpPWpGaD
Amiloride—Polyuria—Methotrexate—muscle cancer	0.00201	0.00718	CcSEcCtD
Amiloride—Aplastic anaemia—Doxorubicin—muscle cancer	0.00198	0.00706	CcSEcCtD
Amiloride—Vertigo—Vincristine—muscle cancer	0.00197	0.00703	CcSEcCtD
Amiloride—Coma—Doxorubicin—muscle cancer	0.00192	0.00687	CcSEcCtD
Amiloride—Anorexia—Dactinomycin—muscle cancer	0.00191	0.00681	CcSEcCtD
Amiloride—Visual disturbance—Methotrexate—muscle cancer	0.00186	0.00665	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00182	0.00651	CcSEcCtD
Amiloride—Alopecia—Etoposide—muscle cancer	0.0018	0.00643	CcSEcCtD
Amiloride—Hepatic function abnormal—Doxorubicin—muscle cancer	0.00175	0.00625	CcSEcCtD
Amiloride—Decreased appetite—Dactinomycin—muscle cancer	0.00174	0.00621	CcSEcCtD
Amiloride—Fatigue—Dactinomycin—muscle cancer	0.00172	0.00616	CcSEcCtD
Amiloride—Back pain—Etoposide—muscle cancer	0.00172	0.00613	CcSEcCtD
Amiloride—Pain—Dactinomycin—muscle cancer	0.00171	0.00611	CcSEcCtD
Amiloride—Muscle spasms—Etoposide—muscle cancer	0.0017	0.00609	CcSEcCtD
Amiloride—Anorexia—Vincristine—muscle cancer	0.0017	0.00609	CcSEcCtD
Amiloride—Feeling abnormal—Dactinomycin—muscle cancer	0.00165	0.00589	CcSEcCtD
Amiloride—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00163	0.00584	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00163	0.00582	CcSEcCtD
Amiloride—Insomnia—Vincristine—muscle cancer	0.00162	0.00578	CcSEcCtD
Amiloride—Paraesthesia—Vincristine—muscle cancer	0.0016	0.00573	CcSEcCtD
Amiloride—Vertigo—Etoposide—muscle cancer	0.00159	0.00569	CcSEcCtD
Amiloride—Abdominal pain—Dactinomycin—muscle cancer	0.00158	0.00565	CcSEcCtD
Amiloride—Decreased appetite—Vincristine—muscle cancer	0.00155	0.00555	CcSEcCtD
Amiloride—Cough—Etoposide—muscle cancer	0.00155	0.00553	CcSEcCtD
Amiloride—Gastrointestinal disorder—Vincristine—muscle cancer	0.00154	0.00551	CcSEcCtD
Amiloride—Fatigue—Vincristine—muscle cancer	0.00154	0.00551	CcSEcCtD
Amiloride—Hyponatraemia—Doxorubicin—muscle cancer	0.00153	0.00548	CcSEcCtD
Amiloride—Constipation—Vincristine—muscle cancer	0.00153	0.00546	CcSEcCtD
Amiloride—Pain—Vincristine—muscle cancer	0.00153	0.00546	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00153	0.00546	CcSEcCtD
Amiloride—Pain in extremity—Doxorubicin—muscle cancer	0.00153	0.00546	CcSEcCtD
Amiloride—Chest pain—Etoposide—muscle cancer	0.00151	0.0054	CcSEcCtD
Amiloride—Gastrointestinal pain—Vincristine—muscle cancer	0.00146	0.00522	CcSEcCtD
Amiloride—Confusional state—Etoposide—muscle cancer	0.00146	0.00522	CcSEcCtD
Amiloride—Asthenia—Dactinomycin—muscle cancer	0.00143	0.00513	CcSEcCtD
Amiloride—Dysuria—Methotrexate—muscle cancer	0.00143	0.00509	CcSEcCtD
Amiloride—Neutropenia—Methotrexate—muscle cancer	0.00143	0.00509	CcSEcCtD
Amiloride—Abdominal pain—Vincristine—muscle cancer	0.00141	0.00505	CcSEcCtD
Amiloride—Erectile dysfunction—Methotrexate—muscle cancer	0.0014	0.00502	CcSEcCtD
Amiloride—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00139	0.00499	CcSEcCtD
Amiloride—Anorexia—Etoposide—muscle cancer	0.00138	0.00493	CcSEcCtD
Amiloride—Diarrhoea—Dactinomycin—muscle cancer	0.00137	0.00489	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—TP73—muscle cancer	0.00136	0.092	CbGpPWpGaD
Amiloride—Depression—Methotrexate—muscle cancer	0.00136	0.00484	CcSEcCtD
Amiloride—Muscular weakness—Doxorubicin—muscle cancer	0.00135	0.00481	CcSEcCtD
Amiloride—Abdominal distension—Doxorubicin—muscle cancer	0.00133	0.00475	CcSEcCtD
Amiloride—Paraesthesia—Etoposide—muscle cancer	0.0013	0.00464	CcSEcCtD
Amiloride—Dyspnoea—Etoposide—muscle cancer	0.00129	0.00461	CcSEcCtD
Amiloride—Somnolence—Etoposide—muscle cancer	0.00129	0.0046	CcSEcCtD
Amiloride—Angina pectoris—Doxorubicin—muscle cancer	0.00129	0.0046	CcSEcCtD
Amiloride—Asthenia—Vincristine—muscle cancer	0.00128	0.00458	CcSEcCtD
Amiloride—Vomiting—Dactinomycin—muscle cancer	0.00127	0.00454	CcSEcCtD
Amiloride—Rash—Dactinomycin—muscle cancer	0.00126	0.00451	CcSEcCtD
Amiloride—AOC1—Tryptophan metabolism—MDM2—muscle cancer	0.00126	0.0853	CbGpPWpGaD
Amiloride—Decreased appetite—Etoposide—muscle cancer	0.00126	0.0045	CcSEcCtD
Amiloride—Gastrointestinal disorder—Etoposide—muscle cancer	0.00125	0.00447	CcSEcCtD
Amiloride—Fatigue—Etoposide—muscle cancer	0.00125	0.00446	CcSEcCtD
Amiloride—Constipation—Etoposide—muscle cancer	0.00124	0.00442	CcSEcCtD
Amiloride—Pain—Etoposide—muscle cancer	0.00124	0.00442	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—muscle cancer	0.00123	0.00441	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—muscle cancer	0.00123	0.00441	CcSEcCtD
Amiloride—Haemoglobin—Methotrexate—muscle cancer	0.00123	0.00438	CcSEcCtD
Amiloride—Diarrhoea—Vincristine—muscle cancer	0.00122	0.00437	CcSEcCtD
Amiloride—Haemorrhage—Methotrexate—muscle cancer	0.00122	0.00436	CcSEcCtD
Amiloride—Pollakiuria—Doxorubicin—muscle cancer	0.00122	0.00436	CcSEcCtD
Amiloride—Feeling abnormal—Etoposide—muscle cancer	0.00119	0.00426	CcSEcCtD
Amiloride—Nausea—Dactinomycin—muscle cancer	0.00119	0.00425	CcSEcCtD
Amiloride—Gastrointestinal pain—Etoposide—muscle cancer	0.00118	0.00423	CcSEcCtD
Amiloride—Dizziness—Vincristine—muscle cancer	0.00118	0.00422	CcSEcCtD
Amiloride—Visual impairment—Methotrexate—muscle cancer	0.00118	0.0042	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—muscle cancer	0.00115	0.0041	CcSEcCtD
Amiloride—Abdominal pain—Etoposide—muscle cancer	0.00114	0.00409	CcSEcCtD
Amiloride—Tinnitus—Methotrexate—muscle cancer	0.00114	0.00407	CcSEcCtD
Amiloride—Vomiting—Vincristine—muscle cancer	0.00114	0.00406	CcSEcCtD
Amiloride—Rash—Vincristine—muscle cancer	0.00113	0.00403	CcSEcCtD
Amiloride—Dermatitis—Vincristine—muscle cancer	0.00113	0.00402	CcSEcCtD
Amiloride—Headache—Vincristine—muscle cancer	0.00112	0.004	CcSEcCtD
Amiloride—Alopecia—Methotrexate—muscle cancer	0.00108	0.00385	CcSEcCtD
Amiloride—Bradycardia—Doxorubicin—muscle cancer	0.00108	0.00384	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—muscle cancer	0.00106	0.0038	CcSEcCtD
Amiloride—Nausea—Vincristine—muscle cancer	0.00106	0.00379	CcSEcCtD
Amiloride—Haemorrhage—Doxorubicin—muscle cancer	0.00106	0.00378	CcSEcCtD
Amiloride—Asthenia—Etoposide—muscle cancer	0.00104	0.00371	CcSEcCtD
Amiloride—Back pain—Methotrexate—muscle cancer	0.00103	0.00367	CcSEcCtD
Amiloride—Pruritus—Etoposide—muscle cancer	0.00102	0.00366	CcSEcCtD
Amiloride—Visual impairment—Doxorubicin—muscle cancer	0.00102	0.00364	CcSEcCtD
Amiloride—Diarrhoea—Etoposide—muscle cancer	0.00099	0.00354	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP73—muscle cancer	0.000986	0.0667	CbGpPWpGaD
Amiloride—Tinnitus—Doxorubicin—muscle cancer	0.000985	0.00352	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—PTCH1—muscle cancer	0.000972	0.0658	CbGpPWpGaD
Amiloride—Dizziness—Etoposide—muscle cancer	0.000957	0.00342	CcSEcCtD
Amiloride—Vertigo—Methotrexate—muscle cancer	0.000954	0.00341	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—muscle cancer	0.000934	0.00334	CcSEcCtD
Amiloride—Cough—Methotrexate—muscle cancer	0.000927	0.00331	CcSEcCtD
Amiloride—Vomiting—Etoposide—muscle cancer	0.00092	0.00329	CcSEcCtD
Amiloride—Rash—Etoposide—muscle cancer	0.000912	0.00326	CcSEcCtD
Amiloride—Dermatitis—Etoposide—muscle cancer	0.000912	0.00326	CcSEcCtD
Amiloride—Headache—Etoposide—muscle cancer	0.000907	0.00324	CcSEcCtD
Amiloride—Flatulence—Doxorubicin—muscle cancer	0.000906	0.00324	CcSEcCtD
Amiloride—Chest pain—Methotrexate—muscle cancer	0.000904	0.00323	CcSEcCtD
Amiloride—Arthralgia—Methotrexate—muscle cancer	0.000904	0.00323	CcSEcCtD
Amiloride—Tension—Doxorubicin—muscle cancer	0.000902	0.00323	CcSEcCtD
Amiloride—Nervousness—Doxorubicin—muscle cancer	0.000893	0.00319	CcSEcCtD
Amiloride—Back pain—Doxorubicin—muscle cancer	0.00089	0.00318	CcSEcCtD
Amiloride—Muscle spasms—Doxorubicin—muscle cancer	0.000884	0.00316	CcSEcCtD
Amiloride—Confusional state—Methotrexate—muscle cancer	0.000874	0.00312	CcSEcCtD
Amiloride—Nausea—Etoposide—muscle cancer	0.00086	0.00307	CcSEcCtD
Amiloride—Vertigo—Doxorubicin—muscle cancer	0.000826	0.00295	CcSEcCtD
Amiloride—Anorexia—Methotrexate—muscle cancer	0.000826	0.00295	CcSEcCtD
Amiloride—Palpitations—Doxorubicin—muscle cancer	0.000813	0.00291	CcSEcCtD
Amiloride—Cough—Doxorubicin—muscle cancer	0.000802	0.00287	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00079	0.00282	CcSEcCtD
Amiloride—Insomnia—Methotrexate—muscle cancer	0.000784	0.0028	CcSEcCtD
Amiloride—Arthralgia—Doxorubicin—muscle cancer	0.000783	0.0028	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—muscle cancer	0.000783	0.0028	CcSEcCtD
Amiloride—Paraesthesia—Methotrexate—muscle cancer	0.000778	0.00278	CcSEcCtD
Amiloride—Dyspnoea—Methotrexate—muscle cancer	0.000773	0.00276	CcSEcCtD
Amiloride—Somnolence—Methotrexate—muscle cancer	0.000771	0.00275	CcSEcCtD
Amiloride—Dyspepsia—Methotrexate—muscle cancer	0.000763	0.00273	CcSEcCtD
Amiloride—Confusional state—Doxorubicin—muscle cancer	0.000757	0.00271	CcSEcCtD
Amiloride—Decreased appetite—Methotrexate—muscle cancer	0.000753	0.00269	CcSEcCtD
Amiloride—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000748	0.00267	CcSEcCtD
Amiloride—Fatigue—Methotrexate—muscle cancer	0.000747	0.00267	CcSEcCtD
Amiloride—Pain—Methotrexate—muscle cancer	0.000741	0.00265	CcSEcCtD
Amiloride—Shock—Doxorubicin—muscle cancer	0.000738	0.00264	CcSEcCtD
Amiloride—Anorexia—Doxorubicin—muscle cancer	0.000715	0.00256	CcSEcCtD
Amiloride—Feeling abnormal—Methotrexate—muscle cancer	0.000714	0.00255	CcSEcCtD
Amiloride—Gastrointestinal pain—Methotrexate—muscle cancer	0.000709	0.00253	CcSEcCtD
Amiloride—Abdominal pain—Methotrexate—muscle cancer	0.000685	0.00245	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000684	0.00244	CcSEcCtD
Amiloride—Insomnia—Doxorubicin—muscle cancer	0.000679	0.00243	CcSEcCtD
Amiloride—Paraesthesia—Doxorubicin—muscle cancer	0.000674	0.00241	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—IGF2—muscle cancer	0.000671	0.0454	CbGpPWpGaD
Amiloride—Dyspnoea—Doxorubicin—muscle cancer	0.000669	0.00239	CcSEcCtD
Amiloride—Somnolence—Doxorubicin—muscle cancer	0.000667	0.00239	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—muscle cancer	0.000661	0.00236	CcSEcCtD
Amiloride—Decreased appetite—Doxorubicin—muscle cancer	0.000652	0.00233	CcSEcCtD
Amiloride—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000648	0.00232	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—muscle cancer	0.000647	0.00231	CcSEcCtD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	0.000642	0.0435	CbGpPWpGaD
Amiloride—Pain—Doxorubicin—muscle cancer	0.000642	0.00229	CcSEcCtD
Amiloride—Constipation—Doxorubicin—muscle cancer	0.000642	0.00229	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.000627	0.0425	CbGpPWpGaD
Amiloride—Asthenia—Methotrexate—muscle cancer	0.000622	0.00222	CcSEcCtD
Amiloride—Feeling abnormal—Doxorubicin—muscle cancer	0.000618	0.00221	CcSEcCtD
Amiloride—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000614	0.00219	CcSEcCtD
Amiloride—Pruritus—Methotrexate—muscle cancer	0.000613	0.00219	CcSEcCtD
Amiloride—Abdominal pain—Doxorubicin—muscle cancer	0.000593	0.00212	CcSEcCtD
Amiloride—Diarrhoea—Methotrexate—muscle cancer	0.000593	0.00212	CcSEcCtD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—muscle cancer	0.000592	0.0401	CbGpPWpGaD
Amiloride—Dizziness—Methotrexate—muscle cancer	0.000573	0.00205	CcSEcCtD
Amiloride—Vomiting—Methotrexate—muscle cancer	0.000551	0.00197	CcSEcCtD
Amiloride—Rash—Methotrexate—muscle cancer	0.000547	0.00195	CcSEcCtD
Amiloride—Dermatitis—Methotrexate—muscle cancer	0.000546	0.00195	CcSEcCtD
Amiloride—Headache—Methotrexate—muscle cancer	0.000543	0.00194	CcSEcCtD
Amiloride—Asthenia—Doxorubicin—muscle cancer	0.000538	0.00192	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—muscle cancer	0.000531	0.0019	CcSEcCtD
Amiloride—Nausea—Methotrexate—muscle cancer	0.000515	0.00184	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—muscle cancer	0.000514	0.00184	CcSEcCtD
Amiloride—Dizziness—Doxorubicin—muscle cancer	0.000496	0.00177	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—muscle cancer	0.000477	0.00171	CcSEcCtD
Amiloride—Rash—Doxorubicin—muscle cancer	0.000473	0.00169	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—muscle cancer	0.000473	0.00169	CcSEcCtD
Amiloride—Headache—Doxorubicin—muscle cancer	0.00047	0.00168	CcSEcCtD
Amiloride—Nausea—Doxorubicin—muscle cancer	0.000446	0.00159	CcSEcCtD
Amiloride—PLAU—Beta3 integrin cell surface interactions—VEGFA—muscle cancer	0.000387	0.0262	CbGpPWpGaD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000382	0.0259	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—ENO2—muscle cancer	0.000372	0.0252	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CDKN2A—muscle cancer	0.000356	0.0241	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CDKN2A—muscle cancer	0.000344	0.0233	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—VEGFA—muscle cancer	0.000281	0.0191	CbGpPWpGaD
Amiloride—PLAU—Beta1 integrin cell surface interactions—VEGFA—muscle cancer	0.000275	0.0186	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—ANGPT2—muscle cancer	0.000264	0.0179	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000257	0.0174	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN2A—muscle cancer	0.00025	0.0169	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000249	0.0169	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MDM2—muscle cancer	0.000242	0.0164	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—TP53—muscle cancer	0.000198	0.0134	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—FH—muscle cancer	0.000171	0.0116	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—muscle cancer	0.000146	0.00992	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000143	0.00969	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	0.000139	0.0094	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—IGF2—muscle cancer	0.000128	0.00869	CbGpPWpGaD
Amiloride—SLC9A1—Disease—ENO2—muscle cancer	0.000105	0.00713	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—MED12—muscle cancer	9.67e-05	0.00655	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HMGA1—muscle cancer	9.57e-05	0.00648	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—ENO2—muscle cancer	8.82e-05	0.00597	CbGpPWpGaD
Amiloride—SLC9A1—Disease—FOXO4—muscle cancer	8.58e-05	0.00581	CbGpPWpGaD
Amiloride—SLC9A1—Disease—FOXO1—muscle cancer	6.34e-05	0.00429	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—VEGFA—muscle cancer	5.38e-05	0.00364	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KIT—muscle cancer	4.83e-05	0.00327	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—muscle cancer	4.07e-05	0.00275	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MDM2—muscle cancer	3.8e-05	0.00258	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—FH—muscle cancer	3.71e-05	0.00251	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTGS2—muscle cancer	3.67e-05	0.00248	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	3.57e-05	0.00242	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—FH—muscle cancer	3.45e-05	0.00234	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	3.33e-05	0.00226	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTGS2—muscle cancer	3.07e-05	0.00208	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—MDM2—muscle cancer	2.74e-05	0.00185	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—MDM2—muscle cancer	2.55e-05	0.00173	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—MED12—muscle cancer	2.09e-05	0.00142	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—MED12—muscle cancer	1.95e-05	0.00132	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ENO2—muscle cancer	1.91e-05	0.00129	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ENO2—muscle cancer	1.78e-05	0.0012	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTGS2—muscle cancer	6.65e-06	0.00045	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTGS2—muscle cancer	6.2e-06	0.00042	CbGpPWpGaD
